You are viewing the site in preview mode

Skip to main content

Table 3 Factors associated with the use of NVP in the first ART regimen using a log-link Poisson model with robust standard errors.

From: Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009

Factor Risk ratio 95% Confidence interval P value
Male sex* 0.95 0.93-0.97 < 0.01
Calendar year of ART initiation (per 2 years) 0.94 0.89-0.99 0.03
Country    
   Kenya ref   
   Uganda 0.71 0.60-0.84 < 0.01
   Tanzania 1.06 1.01-1.12 0.01
Age at ART initiation (years)    
   Quartile 1 (18-31) Ref.   
   Quartile 2 (32-37) 0.98 0.96-1.00 0.04
   Quartile 3 (38-43) 0.97 0.95-1.00 0.04
   Quartile 4 (44-88) 0.98 0.96-1.01 0.14
WHO stage at ART initiation+    
   Stage 1 Ref.   
   Stage 2 1.02 0.99-1.05 0.09
   Stage 3 0.98 0.96-1.01 0.46
   Stage 4 0.91 0.70-0.86 < 0.01
Pre-therapy CD4 level±    
   ≤ 50 cells/mm3 Ref.   
   51-100 cells/mm3 1.04 1.02-1.08 < 0.01
   101-200 cells/mm3 1.07 1.00-1.13 0.02
   > 200 cells/mm3 1.03 0.99-1.07 0.14
Presence of tuberculosis 0.72 0.70-0.75 < 0.01
  1. Each factor is adjusted for all other factors in the table.
  2. * Missing in 106 (0.2%)
  3. + Missing in 2648 (5.4%)
  4. ± Missing in 7283 (15.0%)